| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-115-11-860 |
| P698 | PubMed publication ID | 1952472 |
| P50 | author | V. Craig Jordan | Q7906022 |
| P2093 | author name string | L Cameron | |
| P A Newcomb | |||
| H Leventhal | |||
| R R Love | |||
| D L DeMets | |||
| D A Wiebe | |||
| J Feyzi | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| P304 | page(s) | 860-864 | |
| P577 | publication date | 1991-12-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Effects of tamoxifen on cardiovascular risk factors in postmenopausal women | |
| P478 | volume | 115 |
| Q40912737 | A risk-benefit assessment of tamoxifen therapy |
| Q34950289 | A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health |
| Q73719943 | Abnormal vaginal bleeding from endometrial polyps in a woman receiving tamoxifen therapy for breast cancer: report of a case |
| Q71032636 | Age-related difference in tamoxifen disposition |
| Q28344327 | Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer |
| Q72104014 | Antioxidant benefits of tamoxifen therapy for breast cancer? |
| Q34661852 | Aromatase inhibitors and inactivators for breast cancer therapy |
| Q64118370 | Association between tamoxifen use and acute myocardial infarction in women with breast cancer |
| Q74148534 | Blood chemistry profiles in menopausal women administered tamoxifen for breast cancer |
| Q72950060 | Breast cancer chemoprevention |
| Q42366037 | Can tamoxifen prevent breast cancer? |
| Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
| Q93152835 | Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer |
| Q33649441 | Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy |
| Q41111213 | Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes |
| Q40747949 | Clinical management of women at increased risk for breast cancer |
| Q38697252 | Clinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer Survivors |
| Q71956280 | Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model |
| Q36610798 | Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial |
| Q36684234 | Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer |
| Q77452765 | Drugs causing dyslipoproteinemia |
| Q33694914 | EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium |
| Q34535264 | EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium |
| Q44087732 | Effect of estrogen receptor modulator tamoxifen on blood pressure, plasma renin activity, and renal sodium excretion |
| Q77730611 | Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes |
| Q77916748 | Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma |
| Q44229613 | Effects of anastrozole on lipid metabolism compared with tamoxifen in rats |
| Q28361163 | Effects of anti-oestrogens and beta-estradiol on calcium uptake by cardiac sarcoplasmic reticulum |
| Q57337242 | Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer |
| Q71551027 | Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women |
| Q34767513 | Efficacy and economics of hormonal therapies for advanced breast cancer |
| Q49627304 | Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors. |
| Q36383775 | Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women |
| Q73233835 | Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial |
| Q26785410 | Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors |
| Q36919229 | Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients |
| Q28365007 | First do no harm: extending the debate on the provision of preventive tamoxifen |
| Q24685693 | Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer |
| Q90043140 | G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer |
| Q73338903 | Guidelines for systemic therapy of early stage breast cancer |
| Q72532425 | Hip fracture |
| Q43856978 | Hormone therapy and breast cancer: a review |
| Q40392742 | Hormone-nuclear receptor interactions in health and disease. The oestrogen receptor |
| Q43150387 | How safe is tamoxifen? |
| Q83306280 | Ligand binding by estrogen receptor beta attached to nanospheres measured by fluorescence correlation spectroscopy |
| Q36680024 | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial |
| Q34284548 | Manganese superoxide dismutase: beyond life and death |
| Q40471823 | Mechanisms of action of antiestrogens |
| Q28292288 | Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids |
| Q34742590 | Meta-analysis of vascular and neoplastic events associated with tamoxifen |
| Q40681909 | Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. |
| Q40892619 | Molecular mechanisms and future uses of antiestrogens |
| Q40644017 | Molecular mechanisms of antiestrogen action in breast cancer |
| Q40877161 | Oestrogens and atherosclerotic vascular disease--lipid factors |
| Q71730047 | Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue |
| Q73746465 | Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer |
| Q77896123 | Prevention and treatment of osteoporosis in the elderly |
| Q73179490 | Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat |
| Q32043226 | Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050). |
| Q42809112 | Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen? |
| Q34236652 | Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities |
| Q34118797 | Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats |
| Q33703846 | Raloxifene, a new selective estrogen receptor modulator |
| Q36065502 | Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes |
| Q37292414 | Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. |
| Q73679571 | Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels |
| Q34580753 | Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention |
| Q33540949 | Selective estrogen receptor modulators: Women's panacea for the next millennium? |
| Q33837314 | Selective oestrogen receptor modulation: molecular pharmacology for the millennium |
| Q73534497 | Selective oestrogen receptor modulation: molecular pharmacology for the millennium |
| Q44461124 | Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction |
| Q73105728 | Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen |
| Q33560136 | Systemic therapy in breast cancer: efficacy and cost utility |
| Q34152993 | Tamoxifen ("Nolvadex"): a review. |
| Q24670339 | Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer |
| Q41380460 | Tamoxifen and secondary tumours. An update |
| Q43867271 | Tamoxifen and toremifene cause impairment of learning and memory function in mice |
| Q40385706 | Tamoxifen as adjuvant therapy in breast cancer. Current status |
| Q24241483 | Tamoxifen for early breast cancer |
| Q29619251 | Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group |
| Q41232544 | Tamoxifen in postmenopausal women a safety perspective |
| Q34064360 | Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. |
| Q45265962 | Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina |
| Q34180688 | Tamoxifen: a most unlikely pioneering medicine |
| Q53446252 | Tamoxifen: a personal retrospective. |
| Q41692879 | Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy |
| Q49370321 | The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice |
| Q33730355 | The Molecular Pharmacology of SERMs |
| Q36464743 | The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities |
| Q44737088 | The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs |
| Q26830744 | The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice |
| Q51482151 | The effect of estrogens and antiestrogens in a rat model for hot flush. |
| Q74525431 | The effect of tamoxifen and transdermal 17beta-estradiol on cerebral arterial vessels: a randomized controlled study |
| Q33856027 | The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens |
| Q34315816 | The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators |
| Q34688511 | The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators |
| Q36598699 | The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy |
| Q36292824 | The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor |
| Q40952791 | Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer |
| Q48839905 | Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo |
| Q34674701 | Tissue-specific estrogenic response and molecular mechanisms |
| Q41619937 | Toremifene in postmenopausal breast cancer. Efficacy, safety and cost |
| Q77333249 | p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques |
Search more.